News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in the patients with glioblastoma and anaplastic astrocytoma.

Al's Comment:

 This study says that for a small group of patients (we have to be careful trusting results in small groups), overall survival was doubled by adding Avastin during or right after radiation ends for gbm patients who progress through radiation.


Posted on: 07/25/2018

4. J Neurosurg Sci. 2018 Jul 9. doi: 10.23736/S0390-5616.18.04463-6. [Epub ahead of print]
The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in the patients with glioblastoma and anaplastic astrocytoma.
Yamaguchi S1, Ishi Y1, Motegi H1, Okamoto M1, Kobayashi H2, Hirata K3, Oda Y4, Tanaka S4, Terasaka S1, Houkin K1.
 
Author information:
1. Department of Neurosurgery, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
2. Department of Neurosurgery, Faculty of Medicine, Hokkaido University, Sapporo, Japan - hiro-ko@med.hokudai.ac.jp.
3. Nuclear Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
4. Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Abstract
BACKGROUND:
 
Although newly diagnosed high-grade glioma patients in Japan can receive bevacizumab (BEV) as first-line chemotherapy, randomized clinical trials have not shown a survival benefit for BEV for these patients. In this study, we investigated whether selective add-on BEV for patients with newly diagnosed glioblastoma (GBM) and anaplastic astrocytoma (AA) improves prognosis, in cases where tumors were continuously growing during radiotherapy concomitant with temozolomide (TMZ).
METHODS:
 
We conducted a retrospective survey of the overall survival (OS) of patients with GBM/AAs who were treated in our institution between 2006 and 2016. Patients whose tumors were continuously growing regardless of radiotherapy were categorized as the "progressive" group; remaining patients were categorized as the "non-progressive" group. Since 2013, patients in the "progressive" group received add-on BEV therapy with the Stupp regimen during or just after radiotherapy.
RESULTS:
 
Of 151 GBM/AA patients, 34 (22.5%) were categorized in the "progressive" group. Median OSs of the "progressive" and "non-progressive" groups were 13.2 months and 25.3 months, respectively (P < 0.001). Twelve patients in the "progressive" group received add-on BEV therapy, and their median OS was 20.2 months; whereas for the remaining 22 patients in the "progressive" group who were treated before the BEV era, their median OS was 10.5 months. In the "progressive" group, add-on BEV significantly extended OS (P = 0.018) and was the lone clinical factor of better prognosis.
CONCLUSIONS:
 
We found that, for patients with GBM/AAs whose tumors were continuously growing during radiotherapy, add-on BEV treatment resulted in survival benefits.
PMID: 30035459
Similar articles 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740